Curated Wealth Partners LLC Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Curated Wealth Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 46.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 461 shares of the company’s stock after acquiring an additional 147 shares during the quarter. Curated Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $381,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in LLY. Dividend Assets Capital LLC raised its stake in shares of Eli Lilly and Company by 2.2% during the 1st quarter. Dividend Assets Capital LLC now owns 1,424 shares of the company’s stock valued at $1,176,000 after buying an additional 30 shares during the last quarter. Ibex Wealth Advisors grew its holdings in Eli Lilly and Company by 6.1% in the first quarter. Ibex Wealth Advisors now owns 12,345 shares of the company’s stock valued at $10,196,000 after purchasing an additional 710 shares during the period. First National Bank of Mount Dora Trust Investment Services raised its stake in shares of Eli Lilly and Company by 42.0% during the 1st quarter. First National Bank of Mount Dora Trust Investment Services now owns 14,093 shares of the company’s stock worth $11,640,000 after buying an additional 4,168 shares during the period. Sonora Investment Management Group LLC lifted its position in shares of Eli Lilly and Company by 4.3% during the 1st quarter. Sonora Investment Management Group LLC now owns 3,050 shares of the company’s stock valued at $2,519,000 after buying an additional 127 shares in the last quarter. Finally, Accurate Wealth Management LLC grew its stake in Eli Lilly and Company by 2.2% in the 1st quarter. Accurate Wealth Management LLC now owns 4,273 shares of the company’s stock valued at $3,529,000 after acquiring an additional 93 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.5%

Shares of NYSE:LLY opened at $773.59 on Tuesday. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The firm’s 50-day moving average is $769.95 and its two-hundred day moving average is $800.81. The firm has a market capitalization of $733.16 billion, a PE ratio of 66.06, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm’s revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.58 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.